ASTELLAS PHARMA
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2011-09-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 44
- Registration Number
- NCT01427387
To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01424332
- Locations
- π«π·
SGS Aster, Paris, France
Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01423435
Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 122
- Registration Number
- NCT01416116
- Locations
- π§πͺ
Site 102, Antwerpen, Belgium
π§πͺSite 103, Genk, Belgium
π§πͺSite 101, Roeselare, Belgium
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1484
- Registration Number
- NCT01410747
To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01409603
- Locations
- π«π·
SGS Aster, Paris, France
To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT01409616
- Locations
- π«π·
SGS Aster, Paris, France
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 34
- Registration Number
- NCT01409135
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
πΊπΈUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
πΊπΈUniversity of Colorado, Denver-Aurora, Aurora, Colorado, United States
A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01406158
- Locations
- πΊπΈ
Spaulding Clinical Research, West Bend, Wisconsin, United States
Drug Interaction Study of Isavuconazole and Midazolam
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01406171
- Locations
- πΊπΈ
Covance Clinical Research, Madison, Wisconsin, United States
Β© Copyright 2024. All Rights Reserved by MedPath